Salarius Pharmaceuticals, Inc. (SLRX) Q1 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, today's conference is scheduled to begin shortly. Please continue to stand by and thank you for your patience. Again, ladies and gentlemen, today's conference is scheduled to begin shortly. Please continue to stand by and thank you for your patience. Music Thank you. Thank you. Ladies and gentlemen, thank you for standing by, and welcome to the Quarter 1 2021 Salarius Pharmaceuticals Earnings Webcast and Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session, and instructions will follow at that time. If you should need assistance during the conference, please press star zero. I would now like to turn the conference over to your host today, Mr. Jason Randa of TBRN Strategy Advisor. Sir, please go ahead. Good afternoon, everyone, and thank you for joining Solaris Pharmaceuticals 2021 first quarter and financial and corporate results call. Earlier this afternoon, Solaris Pharmaceuticals issued a press release detailing its financial results for three months and did March 31st, 2021, which we encourage listeners to read. The press release can be found in the news section of solarisfarma.com. Solaris also filed a 10-K this afternoon, which is available on solarisfarma.com and sec.gov. Before beginning today's call, I would like to make the following statement. Today we'll be making certain forward-looking statements about operating metrics, future expectations, plans, events, and circumstances, including statements about our strategy, future operations, and the development and potential effectiveness of our lead investigational drug candidate, Sekla Demstat, and our expectations regarding our capital allocation and cash resources. These statements are based on current expectati...